Holen Sie sich die Stockscreener-App
6.42
2.56%
0.16
Handel nachbörslich:
6.42
Schlusskurs vom Vortag:
$6.26
Offen:
$6.23
24-Stunden-Volumen:
226.08K
Relative Volume:
0.49
Marktkapitalisierung:
$362.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-72.89M
KGV:
-2.6529
EPS:
-2.42
Netto-Cashflow:
$-68.47M
1W Leistung:
+1.74%
1M Leistung:
+9.56%
6M Leistung:
-14.40%
1J Leistung:
-45.45%
1-Tages-Spanne:
$6.20
$6.475
1-Wochen-Bereich:
$5.9404
$6.4894
52-Wochen-Spanne:
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
Firmenname
Astria Therapeutics Inc
Sektor
Branche
Telefon
617-349-1971
Adresse
22 BOSTON WHARF ROAD, BOSTON
Vergleichen Sie ATXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
6.42 | 356.10M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-29 | Eingeleitet | TD Cowen | Buy |
| 2023-03-28 | Eingeleitet | Evercore ISI | Outperform |
Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten
Is Astria Therapeutics Inc. a good long term investmentFree Market Dynamics Reports - jammulinksnews.com
What drives Astria Therapeutics Inc. stock priceExceptional portfolio growth - jammulinksnews.com
What analysts say about Astria Therapeutics Inc. stockRobust financial gains - Autocar Professional
Astria Therapeutics Inc. Stock Analysis and ForecastDynamic growth stocks - Autocar Professional
Published on: 2025-07-19 19:06:02 - jammulinksnews.com
Will Astria Therapeutics Inc. stock split in the near futureFree Stock Market Trend Analysis - Newser
why astria therapeutics inc. stock attracts strong analyst attentionPortfolio Boosting Stock Alerts - Newser
How Astria Therapeutics Inc. stock performs during market volatilityTechnical Breakout List - Newser
What makes Astria Therapeutics Inc. stock price move sharplyFree Access to Stock Community - beatles.ru
Why Astria Therapeutics Inc. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
Astria: Betting On Navenibart In The Crowded HAE Arena - Seeking Alpha
Astria Therapeutics (ATXS) Soars 5.62% on Positive Trial Results - AInvest
Astria Therapeutics Inc (ATXS) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit - BioSpace
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Buy” by Analysts - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 - BioSpace
Trading (ATXS) With Integrated Risk Controls - news.stocktradersdaily.com
(ATXS) Trading Report - news.stocktradersdaily.com
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit - BioSpace
Astria Therapeutics to Participate in Upcoming Oppenheimer Innov - GuruFocus
Astria CEO Discusses Breakthrough Dermatology Treatments at Major Oppenheimer Summit - Stock Titan
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress - BioSpace
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $30.00 - Defense World
HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World
Astria Therapeutics (ATXS) Receives Reiterated Buy Rating and $1 - GuruFocus
Astria Therapeutics (ATXS) Reports Promising Results for Navenib - GuruFocus
Astria Therapeutics Announces Positive Initial Results from the - GuruFocus
Astria Therapeutics Says New Data Back Navenibart Dose Regimen for Hereditary Angioedema - MarketScreener
California State Teachers Retirement System Increases Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Two Sigma Investments LP Sells 2,042 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Finanzdaten der Astria Therapeutics Inc-Aktie (ATXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):